The transaction is sourced from an SEC EDGAR Form 8-K filing published on April 3, 2025. Based on the facts provided, the deal's status is pending regulatory approval.
On the financial advisory side, Morgan Stanley & Co. LLC served as financial advisor to Globus Medical, the acquirer, and is identified as the lead advisor on that side. BofA Securities, Inc. served as financial advisor to Nevro Corp., the target, and is likewise identified as the lead advisor for the target.
On the legal side, Latham & Watkins LLP served as legal advisor to Nevro Corp., the target, while Wyrick Robbins Yates & Ponton LLP served as legal advisor to Globus Medical, the acquirer.
As the facts explicitly note, the consideration structure for this acquisition is not specified in the excerpt available, meaning no detail on whether the transaction involves cash, stock, or a combination of the two is included in the material provided.
Several elements of this deal remain undisclosed. The deal value is explicitly noted as not stated in the source document, and the consideration structure itself is explicitly flagged as not specified in the available excerpt. No expected closing date is given, and no detail on required regulatory approvals is provided in the facts available.